Aura Biosciences nabs $40M Series D

Aura Biosciences, a developer of medicines for the treatment of eye cancer, has raised $40 million in a round led by Medicxi. Founded in 2009 and based in the Boston area, the clinical-stage biotech company will use the funds in part to advance the development of its lead drug candidate. Aura was most recently valued at $65 million with a $42 million round.

Additional Investors